How do we get from hyperexcitability to excitotoxicity in amyotrophic lateral sclerosis?
Brain · 2024
DOI: 10.1093/brain/awae039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain, 2024. Verfasst von G Lorenzo Odierna und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tasmanian School of Medicine, University of Tasmania, Hobart, TAS 7000, Australia. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Motor Neurons, Glutamic Acid. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Motor Neuron Disease Research Australia, National Health and Medical Research Council of Australia.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis is a devastating neurodegenerative disease that, at present, has no effective cure. Evidence of increased circulating glutamate and hyperexcitability of the motor cortex in patients with amyotrophic lateral sclerosis have provided an empirical support base for the ‘dying forward’ excitotoxicity hypothesis. The hypothesis postulates that increased activation of upper motor neurons spreads pathology to lower motor neurons in the spinal cord in the form of excessive glutamate release, which triggers excitotoxic processes. Many clinical trials have focused on therapies that target excitotoxicity via dampening neuronal activation, but not all are effective. As such, there is a growing tension between the rising tide of evidence for the ‘dying forward’ excitotoxicity hypothesis and the failure of therapies that target neuronal activation. One possible solution to these contradictory outcomes is that our interpretation of the current evidence requires revision in the context of appreciating the complexity of the nervous system and the limitations of the neurobiological assays we use to study it. In this review we provide an evaluation of evidence relevant to the ‘dying forward’ excitotoxicity hypothesis and by doing so, identify key gaps in our knowledge that need to be addressed. We hope to provide a road map from hyperexcitability to excitotoxicity so that we can better develop therapies for patients suffering from amyotrophic lateral sclerosis. We conclude that studies of upper motor neuron activity and their synaptic output will play a decisive role in the future of amyotrophic lateral sclerosis therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tasmanian School of Medicine, University of Tasmania, Hobart, TAS 7000, Australia.
- Brain and Nerve Research Center, The University of Sydney, Sydney 2050, Australia.
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia.
- Department of Pharmaceutical and Pharmacological Sciences, Center for Neurosciences, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium.
- The Wicking Dementia Centre, University of Tasmania, Hobart, TAS 7000, Australia.
ORCID-Profile: Catherine Blizzard
Förderung
- Motor Neuron Disease Research Australia
- National Health and Medical Research Council of Australia
Zitieren
APA
Odierna, G. L., Vucic, S., Dyer, M., Dickson, T., Woodhouse, A., & Blizzard, C. (2024). How do we get from hyperexcitability to excitotoxicity in amyotrophic lateral sclerosis?. Brain. https://doi.org/10.1093/brain/awae039
Vancouver
Odierna GL, Vucic S, Dyer M, Dickson T, Woodhouse A, Blizzard C. How do we get from hyperexcitability to excitotoxicity in amyotrophic lateral sclerosis?. Brain. 2024. doi:10.1093/brain/awae039
BibTeX
@article{Odierna2024,
author = {Odierna, G Lorenzo and Vucic, Steve and Dyer, Marcus and Dickson, Tracey and Woodhouse, Adele and Blizzard, Catherine},
title = {How do we get from hyperexcitability to excitotoxicity in amyotrophic lateral sclerosis?},
journal = {Brain},
year = {2024},
doi = {10.1093/brain/awae039}
}
EUVIMED